

New York Biotechnology Association



**Media Contact:**

Nathan Tinker  
Executive Director  
New York Biotechnology Association  
631-444-8895

**NYBA ANNOUNCES SPEAKER LINEUP FOR THE NYBA 20TH ANNUAL MEETING, APRIL 6-7, 2011 IN NYC**

NEW YORK (Feb 16 2011) -- New York Biotechnology Association (NYBA), the voice of New York State's life science industry, today announced the preliminary speaker list for the NYBA 20th Annual Meeting, April 6-7, at the Marriott Marquis Hotel in New York City. Speakers representing more than 100 companies will discuss the issues and opportunities available to New York's bioscience industry.

The NYBA 20th Annual Meeting program ([tinyurl.com/nyba2011](http://tinyurl.com/nyba2011)) will feature more than 30 panel sessions on key industry topics, including Drugs, Diagnostics and Medical Devices; Advances in Bioscience; Investment and Financial Issues; The Business of Biotech; Regulatory and Policy Challenges; and Legal and IP Issues.

The final program is still in development, but the preliminary list of leading scientists and industry leaders scheduled to speak at the conference includes

- Adam Stern, Director, Prolor Biotech
- Adolfo Garcia-Sastre, Professor, Department of Microbiology and Co-Director of the Emerging Pathogens Institute, Sinai School of Medicine
- Ali Andilibi, Branch Chief, SBIR Development Center, National Cancer Institute
- Andrew Weisenfeld, Senior Managing Director, MTS HealthPartners
- Azra Raza, Professor of Medicine, Director of MDS Center, Columbia University

- Braham Shroot, CEO, Signum Biosciences
- Charles Rice, Maurice R. And Corinne P. Greenberg Professor, The Rockefeller University; Scientific and Executive Director, Center for the Study of Hepatitis C
- Charles Weiss, Kenyon & Kenyon LLP
- Chester A. Bisbee, Office of Technology Licensing & Industry Relations, SUNY Stony Brook
- Chris Kabel, Cancer Genetics Inc
- Craig Bihari, Executive Coaching Group
- Craig Jordan, Professor of Medicine, Division of Hematology/Oncology, James P Wilmot Cancer Center, Professor of Biomedical Genetics, University of Rochester School of Medicine
- Craig Keyes, Emblem Health (GHI/HIP Health)
- Daniel Teper, CEO, Immune Pharmaceuticals
- David Beylin, Program Manager, SBIR Development Center, National Cancer Institute
- Deborah A. Somerville, Kenyon & Kenyon LLP
- Deborah Lu, Vedder Price
- Diane Borghoff, Health Research Inc.
- Doug Given, President and CEO, Vivaldi Biosciences and Partner, Bay City Capital
- Edward Pollack, International AIDS Vaccine Initiative
- Eric Vieira, Assistant Director, Office of Technology & Business Development, Mount Sinai Medical Center
- Gail Brown, SVP & CMO, Telik, Inc.
- Henry Pan, CEO, Renascions Corporation
- Herma Schmitz, Executive Coaching Group
- Jane Wasman, General Counsel, Acorda Therapeutics
- Jeffrey Greenberg, Associate Director, Clinical & Translational Sciences, Division of Rheumatology, NYU School of Medicine; Director, Arthritis Translational Registry & Biorepository, NYU Hospital for Joint Diseases

- Joan Kiely, Center for Science and Mathematics, SUNY Stony Brook
- Joel Marcus, CEO, Alexandria Real Estate Equities
- Joel Papernik, Partner, Mintz Levin
- John Castellani, CEO, PhRMA
- Jonathan Silverstein, Partner, Orbimed
- Jules T. Mitchel, President, Target Health Inc
- Kevin Brayton, Triumvirate Environmental Inc.
- Kumar Shah, CEO, Endocrine Technologies LLC
- Lillian Stern, Stern Investor Relations
- Mark Wallack, CEO, CureVax
- Michael Bui, Bayer HealthCare Pharmaceuticals
- Nathan Tinker, Executive Director, NYBA
- Peter Robinson, VP and COO, University of Rochester Medical Center;  
Chairman, NYBA Board of Directors
- Raj Somasundaram, The Wister Institute
- Raj Tiwari, New York Medical College
- Richard Clark, The Wound Healing Laboratory, SUNY Stony Brook
- Rob Shovlin, President and CEO, Aureon Biosciences
- Robert Easton, Chairman, Scisive Consulting
- Robert Gallo, Health Research Inc.
- Robert Nowinski, CEO, ContraFect Corp
- Ron Cohen, CEO, Acorda Therapeutics
- Sally Temple, Founder & Scientific Director, Neural Stem Cell Institute
- Samuel D. Waksal, CEO, Kadmon Pharmaceuticals
- Spiro Rombotis, President and CEO, Cyclacel Pharmaceuticals
- Stephen Chang, New York Stem Cell Foundation
- Stephen Sands, Vice Chairman of U.S. Investment Banking and Global  
Co-Head of Lazard's Healthcare Group, Lazard Freres & Co., LLC
- Thomas C. Gallagher, Kadmon Pharmaceuticals
- Thomas Kowalski, Vedder Price
- Tony Albino, EVP for Science and Technology, Signal Genetics

- Zhi Hong, Head of Infectious Disease CEDD, Senior Vice President, GlaxoSmithKline
- ZMG Sarwar Jahangir, Kingsborough Community College

Concurrent to these speakers, in the Innovation Alley Poster Session the next generation of scientists and emerging companies will exhibit their groundbreaking scientific research, work that will enable the next great bioscience discovery.

And in the Corporate Showcase, CEOs and top executives from more than 30 leading public and private companies will present their businesses to potential investors, strategic partners, customers and partners.

In all, some 700 attendees will converge on the Marriott Marquis Hotel in Times Square to learn, network, discuss, contemplate, debate and engage.

The NYBA Annual Meeting brings together hundreds of bioscience professionals from the New York, the Northeast and the world for two days of high-energy insight and information. For more information go to [www.nyba.org](http://www.nyba.org) or contact Patricia Wadington, NYBA Membership Director, at 631-444-8895.

###

### **About New York Biotechnology Association**

NYBA is the leading advocate for advancing the success of the life science industry in New York State and is its main representative to state policy makers, the media and communities. NYBA's mission is to support the development and growth of New York's life science industry, and serve our members and the life science community by providing a network for information exchange, shared services and collective action. NYBA's membership comprises bioscience companies, world-class research institutions and related professional services. Under the banner of The Cures Start Here®, the Association's goal is to amplify the success New York has had and continues to have in discovering major medical advances and growing a vibrant biotech industry.